Older News Items

4th-April-2022

New insights into the genetic etiology of Alzheimers disease and related dementias

28th-March-2022

A computational model of neurodegeneration in Alzheimers disease

28th-March-2022

FDA-approved drug shows improved cognitive function in people with Alzheimers Disease and a mouse model of Down syndrome

16th-March-2022

Four genes (TMEM106B, RAB27B, GMPPB, and NEGR1) affect depression by influencing protein and gene expression level

7th-March-2022

Neurons detect cognitive boundaries to structure episodic memories in humans

26th-February-2022

Sauna-like conditions or menthol treatment reduce tau phosphorylation through mild hyperthermia

15th-February-2022

Antidepressant effects of psilocybin-assisted therapy may be durable at least through 12months

20th-January-2022

Microglia and Alzheimer’s

11th-January-2022

Cannabinol (CBN) maintains key parameters of mitochondrial function for neuroprotection

10th-January-2022

Male and female brain differences and treating depression

20th-December-2021

Plasma p-tau217 best predicted subsequent tau-tangle accumulation in people with preclinical AD

6th-December-2021

Viagra linked to almost 70% lower risk of Alzheimers

29th-October-2021

In vivo rate-determining steps of tau seed accumulation in Alzheimer’s disease

29th-October-2021

A double-blind randomized controlled trial shows transcranial magnetic stimulation caused remission in 79% of trial participants with severe depression

11th-October-2021

Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease